Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953150 | 1.00 | DPP4 (0.39) | DPP4MAPTHTR2CGAAJAK2 | |
| SCHEMBL954848 | 1.00 | DPP4 (0.39) | DPP4MAPTHTR2CGAAJAK2 | |
| SCHEMBL8206794 | 1.00 | DPP4 (0.39) | DPP4MAPTHTR2CGAAJAK2 | |
| Hydrochloric Acid SCHEMBL17560459 | 0.98 | DPP4 (0.38) | DPP4MAPTHTR2CGAAJAK2 | |
| Hydrochloric Acid SCHEMBL17560457 | 0.98 | DPP4 (0.38) | DPP4MAPTHTR2CGAAJAK2 | |
| SCHEMBL18705721 | 0.89 | DPP4 (0.37) | DPP4MAPTHTR2CJAK2JAK1 | |
| SCHEMBL18705711 | 0.89 | DPP4 (0.37) | DPP4MAPTHTR2CJAK2JAK1 | |
| SCHEMBL18705712 | 0.89 | DPP4 (0.37) | DPP4MAPTHTR2CJAK2JAK1 | |
| SCHEMBL572253 | 0.86 | LMNA (0.43) | DPP4HTR2CTSHRALDH1A1LMNA | |
| SCHEMBL13486466 | 0.86 | LMNA (0.43) | DPP4HTR2CTSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-8518912-B2 | Phosphonic acid derivates and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| EP-2225253-B1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8048881-B2 | Uding 4-aminocarbonyl-pyrimidine; vascular disorders; cardiovascular disorders; thrombosis; brain disorders; vision defects | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-0976749-A1 | Process for preparing quinolone and naphthyridone carboxylic acids | Pfizer Products Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
| CN-1048484-C | A process for preparing a composition containing benzoheterocycles | OTSUKA PHARMA CO LTD (JP) | 2000-01-19 | — | — | CN | disclosed |
| CN-1183781-A | Novel heterocyclic compounds | NOVO NORDISK AS (DK) | 1998-06-03 | — | — | CN | disclosed |
| EP-0727421-A1 | Agents for improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-08-21 | — | — | EP | disclosed |
| US-5026853-A | Sleep and cardiovascular disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-06-25 | — | — | US | disclosed |
| US-4968684-A | N-ARYL-PIPERAZINEALKANAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-06 | — | — | US | disclosed |
| WO-1990000551-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0350950-A1 | Process for the preparation of quinoline antibacterial compounds | ABBOTT LABORATORIES (US) | 1990-01-17 | — | — | EP | disclosed |
| US-4880808-A | SEDATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-11-14 | — | — | US | disclosed |
| EP-0285219-A2 | Method of improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | DPP4 1890/4885MAPT 4875/4885HTR2C 737/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | DPP4 3351/4885MAPT 2731/4885HTR2C 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.